<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570245</url>
  </required_header>
  <id_info>
    <org_study_id>VICER1</org_study_id>
    <nct_id>NCT00570245</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Nitric Oxide in Patients Going Through Lung Transplantation</brief_title>
  <official_title>A Pilot, Single Center Prospective, With Parallel Groups, Controlled and Open to Evaluate the Efficacy of Nitric Oxide for Inhalation in Lung Donors and in the Prevention of Reperfusion Injury.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide in&#xD;
      prevention of lung graft dysfunction due to ischemia-reperfusion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Pilot, single-center, prospective, randomized, parallel-group, controlled, open-label&#xD;
           trial.&#xD;
&#xD;
        -  Sixty lung donors will be analyzed, making a comparative study between donors receiving&#xD;
           NO for 3 hours prior to removal of the organ versus a control group to which NO will not&#xD;
           be administered.&#xD;
&#xD;
        -  A Swan-Ganz catheter will be placed to determine PVR, PAP, MV, and PCP; and blood gases&#xD;
           will be done after arterial cannulation to determine FiO2/PaO2 hourly. Also, standard&#xD;
           blood chemistry, hematology, coagulation parameters, and arterial blood gas.&#xD;
&#xD;
        -  Prior to NO administration and before procurement, a BAL (bronchoalveolar lavage) will&#xD;
           be done to determine the presence of leukocytes, predominantly neutrophils, IL-1, IL-6,&#xD;
           IL-8, IL-10, TNF, and proteins as well as obtaining secretions for culture.&#xD;
&#xD;
        -  The dosage of NO will be 10ppm, with NO2 and methemoglobinemia being monitored&#xD;
           exhaustively.&#xD;
&#xD;
        -  In the operating room and prior to lung removal, a new BAL will be done and the&#xD;
           anti-inflammatory agents described above will be determined.&#xD;
&#xD;
        -  Organ removal and the preservation fluid used will be standard, according to the&#xD;
           established surgical protocol.&#xD;
&#xD;
        -  Anesthesia: methylprednisolone 1 g will be administered before organ extraction;&#xD;
           hemodynamic determinations of mAP, PAP, CVP, MV, and hourly urinary output and arterial&#xD;
           blood gas.&#xD;
&#xD;
        -  Hemodynamic and respiratory determinations will be made in the lung receptors: mAP,&#xD;
           mPAP, PVR, MV, PCP, DO2, Qs/Qt, and CVP as well as gas determinations every 30 minutes,&#xD;
           blood chemistry, hematology, and coagulation immediately after reperfusion. A BAL will&#xD;
           also be done after anesthesia induction.&#xD;
&#xD;
        -  Incidents during surgery will be recorded, especially the need for extracorporeal&#xD;
           circulation as well as transfusion requirements and ischemia times.&#xD;
&#xD;
        -  After surgery, another BAL will be done both 24 hours and 48 hours after return to the&#xD;
           Recovery Unit. Hemodynamic and respiratory parameters will be monitored every 4 hours&#xD;
           for the first 48 hours after surgery, as well as arterial blood gases.&#xD;
&#xD;
        -  Blood chemistry will be done every 12 hours along with coagulation and hematology tests.&#xD;
&#xD;
        -  Chest x-ray on admission and daily to determine the degree of the patient's edema over&#xD;
           the first 48 hours.&#xD;
&#xD;
        -  Drug administration: the NO will be administered in the respirator intake at a dose of&#xD;
           10ppm for 48 hours. A monitor will be used showing the gas dosage continuously, as well&#xD;
           as NO2 and methemoglobinemia.&#xD;
&#xD;
        -  The inflammatory agents (TNF, IL-1, IL-2, IL-6, IL-8, and IL-10) will be determined with&#xD;
           the ELISA technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Edema and mPAP</measure>
    <time_frame>4 - 48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Neither donors or recipients will receive NO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donor will not receive NO, recipient will receive up to 48 hours of NO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric oxide</intervention_name>
    <description>inhalation, 10 ppm, for up to 48 hours</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric oxide</intervention_name>
    <description>inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a lung graft scheduled&#xD;
&#xD;
          -  Males and females aged 18 to 65&#xD;
&#xD;
          -  Signed informed consent approved by the IRB/EC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled bacterial infection&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min&#xD;
&#xD;
          -  Severe extrapulmonary organic dysfunction&#xD;
&#xD;
          -  Continuing smoking habit&#xD;
&#xD;
          -  Neoplastic disease (2-5 years free of tumor, depending on type)&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Severe osteoporosis&#xD;
&#xD;
          -  Active peptic ulcer&#xD;
&#xD;
          -  Progressive neuromuscular disease&#xD;
&#xD;
          -  Active limiting systemic disease. Complicated diabetes.&#xD;
&#xD;
          -  Any contraindication based on the judgement of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario Vicente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Moreno I, Vicente R, Ramos F, Vicente JL, Barberá M. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc. 2007 Sep;39(7):2425-6.</citation>
    <PMID>17889209</PMID>
  </reference>
  <reference>
    <citation>Moreno I, Mir A, Vicente R, Pajares A, Ramos F, Vicente JL, Barbera M. Analysis of interleukin-6 and interleukin-8 in lung transplantation: correlation with nitric oxide administration. Transplant Proc. 2008 Nov;40(9):3082-4. doi: 10.1016/j.transproceed.2008.08.124.</citation>
    <PMID>19010201</PMID>
  </reference>
  <reference>
    <citation>Moreno I, Vicente R, Mir A, León I, Ramos F, Vicente JL, Barbera M. Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation. Transplant Proc. 2009 Jul-Aug;41(6):2210-2. doi: 10.1016/j.transproceed.2009.05.019.</citation>
    <PMID>19715875</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

